Unlock Exclusive Discounts & Flash Sales! Click Here to Join the Deals on Every Wednesday!

In Vivo Pharmacodynamic Evaluation of B-hCD20 EL4 Cells Induced Tumor Models (CAT#: STEM-AE-0159-LGZ)

Introduction

The human CD20 coding sequence was inserted into the ROSA26 locus in EL4 cells. Human CD20 is highly expressed on the surface of B-hCD20 EL4 cells.
B-hCD20 EL4 cells have the capability to establish tumors in vivo and can be used for efficacy studies.
Common name: B-hCD20 EL4
Aliases: MS4A1, Bp35, CVID5
Organism: Mouse
Tissue types: Lymphoma
Disease: Lymphoma
Strain: C57BL/6N
Tissue: T lymphocyte




Principle

Tumor-associated antigen (TAA) refers to antigen molecules that are specific or highly expressed in Tumor cells but absent or underexpressed in healthy cells, and are involved in the proliferation, differentiation, and migration of tumor cells. This makes TAA a potential effective molecular target of antitumor drugs. Taa-targeted drugs can kill tumor cells by mediating ADCC, CDC, and activating immune response. For this type of drug, subcutaneous inoculation of wild-type mice or in situ inoculation of humanized mouse cell lines can be used to evaluate its efficacy. We have developed a series of humanized cell lines for pharmacodynamic evaluation based on the current market demand for TAA target drug development. Some of the TAA targets are expressed in healthy tissues and cells and play important physiological functions. The drugs of these targets may have serious toxic and side effects, so we can provide the corresponding humanized animal models for drug safety evaluation.

Applications

Lymphoma

Procedure

1. Disease model construction.
2. Mice dosing.
3. Efficacy monitoring.
4. Biochemical detection of tissue samples.

Materials

• Sample Type: liquid or powder
Advertisement